Benchmarks trade near flat line; breadth negative

Image
Capital Market
Last Updated : Aug 17 2021 | 12:04 PM IST
Equity indices traded near the flat line with tiny losses in morning trade. The Nifty hovered above the 16,550 level. Healthcare and IT stocks advanced while banks and financial shares were under pressure.

At 10:25 IST, the barometer index, the S&P BSE Sensex, was down 15.13 points at 55,567.78. The Nifty 50 index fell 4.25 points or 0.03% at 16,558.20.

The Sensex hit record high of 55,688.50 while Nifty scaled record high of 16,591.40 in early trade.

In broader market, the S&P BSE Mid-Cap index was up 0.39% while the S&P BSE Small-Cap index was up 0.43%.

The market breadth, indicating the overall health of the market, was negative. On the BSE, 1267 shares rose and 1556 shares fell. A total of 109 shares were unchanged.

COVID-19 Update:

Total COVID-19 confirmed cases worldwide stood at 207,824,763 with 4,370,906 global deaths.

India reported 369,846 active cases of COVID-19 infection and 432,079 deaths, according to the data from the Ministry of Health and Family Welfare, Government of India.

Buzzing Index:

The Nifty Healthcare index gained 1.2% to 8,955.85, snapping its three day losing streak. The index dropped 2.33% in the past three sessions.

Apollo Hospitals (up 4.8%), Fortis Healthcare (up 1.84%), Sanofi (up 1.78%), Cipla (up 1.77%), Sun Pharmaceuticals (up 1.47%), Aurobindo Pharma (up 1.35%), Lupin (up 1.16%) and IPCA Lab (up 1.12%) were top gainers in healthcare space.

Stocks in Spotlight:

RailTel Corporation of India rose 0.81%. The company received two works of tunnel communication of Central Railway from Indian Railways with completion period of 12 months. The total anticipated project cost of the work is Rs 38.82 crore.

Suven Life Sciences jumped 8.25% after the company announced phase three clinical trial of SUVN-502 (Masupirdine), an antagonist for treatment of agitation and aggression in Alzheimer's type dementias. The multi-center study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result expected by the end of year 2024.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 17 2021 | 10:30 AM IST

Next Story